1. FM-WEBSITE

Search Page

[current-page:query:search_api_aggregation_1]

Filter and Sort

Content type

681 - 690 of 2170
Paper

Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)

António Almeida 2015. BLOOD
Paper

REAL-WORLD EVIDENCE OF IRON CHELATION THERAPY IN TRANSFUSION DEPENDENT MDS PATIENTS: A PORTUGUESE HOSPITAL REGISTRY

António Almeida 2015. VALUE IN HEALTH
Paper

STUDY PHASE 3 OF LENALIDOMIDE (LEN) IN PATIENTS (PTES) WITH MYELODYSPLASTIC SYNDROME (SMD) WITHOUT DEL(5Q) OF LOW RISK AND WITH TRANSFUSIONAL DEPENDENCE (DT), REFRACTORIES OR NON RESPONSIVE TO STIMULATING AGENTS OF ERYTHROPOIESIS

António Almeida 2015. HAEMATOLOGICA
Paper

CLINICAL FACTORS PREDISPOSING TO ACHIEVEMENT OF RBC TRANSFUSION INDEPENDENCEIN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES) WITHOUT DEL(5q) IN MDS-005 STUDY

António Almeida 2015. HAEMATOLOGICA
Paper

MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS ERYTHROPOIETIN ON RBC TRANSFUSION INDEPENDENCE IN LENALIDOMIDE-TREATED PATIENTS WITH LOW OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES WITHOUT DEL(5Q)

António Almeida 2015. HAEMATOLOGICA